MetaCap

Vaxcyte (PCVX) vs Qiagen N.V. (QGEN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Vaxcyte (PCVX) has outperformed Qiagen N.V. (QGEN) over the past year, gaining 15.9% versus a gain of 5.3%. Over five years, PCVX leads with a +178.9% price change compared with -15.4% for QGEN. Qiagen N.V. is the larger company by market cap ($10.18 billion vs $8.77 billion), about 1.2 times the size.

Qiagen N.V. pays a dividend yielding 0.71%, while Vaxcyte does not currently pay one.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PCVX+15.93%QGEN+5.25%
+59%+12%-35%
Nov 21, 20251 yearNov 20, 2026
PCVX+143.90%QGEN-13.86%
+433%+184%-65%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PCVX versus QGEN key metrics
MetricPCVXQGEN
Share price$55.39$49.30
Market cap$8.77B$10.18B
1-day change-5.09%-0.66%
YTD return+20.05%+9.63%
1-year return+15.93%+5.25%
5-year return+178.90%-15.40%
P/E ratio (TTM)—26.65
Forward P/E—18.48
EPS (TTM)$-8.05$1.85
Dividend yield0.00%0.71%
Annual dividend$0.00$0.35
Revenue (latest FY)—$2.09B
Revenue growth (YoY)—+5.65%
Net income (latest FY)$-766.63M$424.88M
Gross margin—62.18%
Operating margin—22.29%
Net margin—20.33%
52-week high$90.75$57.82
52-week low$42.40$32.53
Distance from 52-week high-38.96%-14.74%
Analyst consensusnonehold
Avg. price target upside+110.15%+0.95%
Average volume2.19M3.65M
Shares outstanding158.30M206.50M
Employees5075,400
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PCVX has outperformed QGEN by 10.7 percentage points over the past year.

About Vaxcyte

PCVX stock →

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 507 employees

About Qiagen N.V.

QGEN stock →

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5,400 employees

PCVX vs QGEN FAQ

Which is bigger, Vaxcyte or Qiagen N.V.?

Qiagen N.V. (QGEN) is larger, with a market capitalization of $10.18B compared with $8.77B for Vaxcyte (PCVX).

Which stock has performed better over the past year, PCVX or QGEN?

PCVX returned +15.93% over the past 12 months, compared with +5.25% for QGEN (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, Vaxcyte or Qiagen N.V.?

Qiagen N.V. pays a dividend yielding 0.71%, while Vaxcyte does not currently pay a regular dividend.

Are Vaxcyte and Qiagen N.V. in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons